Onconova Therapeutics Received an Analyst Upgrade and Take-Two Interactive Software Reported Strong Earnings
Onconova Therapeutics is a classic biotechnology company located near Philadelphia, Pennsylvania. They are not a small cap, but a micro-cap with a market capitalization of $255.541 million.
On Tuesday, analysts Etzer Darout from Guggenheim placed a buy rating on Onconova, setting the price target to $4.00. Darout wrote that their drug, which is targeting CDK, a rare disease, could penetrate the market easily and claim an 8-billion-dollar opportunity in the area. For a micro-cap, that is a huge opportunity that could lead to a major jump in the share value.
Onconova rose by 75.04% to $1.08 on Tuesday, which was very promising.
Take-Two Interactive Software
Take-Two develops games and entertainment services for consumers worldwide. You might have played one of their games, the famous ones being the Grand Theft Auto series, the 2K sports series, and the Red Dead Redemption series. Take-Two is a relatively large company, with their market cap sitting at $19.314 billion.
Take-Two reported earnings after the bell on Tuesday, and things were very promising. Their net revenue grew by 10 percent to $839.4 million, with much of the money coming from games like NBA 2K21 and Grand Theft Auto V. The company also noted that the lockdowns created a sales boost for their games, but the country is reopening, which creates a confusing situation.
After market close, Take-Two jumped to $173.85, up 3.67%.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.